We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Epistem Announces the Successful Evaluation of New RNA-AMP™ Technology
News

Epistem Announces the Successful Evaluation of New RNA-AMP™ Technology

Epistem Announces the Successful Evaluation of New RNA-AMP™ Technology
News

Epistem Announces the Successful Evaluation of New RNA-AMP™ Technology

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Epistem Announces the Successful Evaluation of New RNA-AMP™ Technology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Epistem Holdings Plc has announced the successful evaluation of RNA-Amp™ for single cell expression profiling. The results have been published in BMC Genomics (Rothwell et al. (2014). 15:1129) and compare amplified cDNA derived from three RNA-Amplification kits (Miltenyi MACS™, NuGEN Ovation® One-Direct and Epistem RNA-Amp™). The authors concluded that Epistem's RNA-Amp™ kit exhibited the highest sensitivity and reproducibility.

In addition, Affymetrix microarray data demonstrated that cDNA generated from single cells using Epistem RNA-Amp™ produced faithful representative cDNA relative to unamplified reference controls. Strong platform correlations were also reported following the assessment of RNA-Amp™ cDNA by RNA-Seq and high density qPCR.

Using RNA-Amp™ amplified material, the authors were able to identify transcriptional differences in cancer initiating cells (CICs) following RNA-Seq analysis. The authors concluded that the combined results confirmed the sensitivity and reproducibility of the Epistem RNA-Amp™ technology for profiling in small cell populations.

Epistem's RNA-Amp™ technology is a highly sensitive and reproducible method to derive cDNA from picogram to nanogram quantities of RNA. RNA-Amp™ can be used with samples containing extracted RNA or performs well with samples directly, without the need for RNA isolation.

The amplified cDNA derived from Epistem kits is platform agnostic and can be used in conjunction with a range of instrument manufacturer's microarray, RT-qPCR and Next Generation Sequencing products. Epistem will be presenting the RNA-Amp™ technology at the Molecular Medicine Tri-Conference in San Francisco 15-20th February.

Matthew Walls, Epistem CEO commented; "We are delighted with the results of the evaluation study which alongside our existing internal applications in biomarker discovery and key gene regulation, opens up the possibility of producing RNA Amp™ in a kit form for Next Generation Sequencing."

Advertisement